top of page
Recent Research
ROG:VX: APHINITY headline positive but await full data
Awaiting full data: Roche announced that APHINITY met its primary endpoint , but as expected details are to be published at an upcoming...
Mar 2, 2017
ROG.VX: APHINITY too close for comfort
We present the third update of our APHINITY analysis, originally published two years ago and find the risks of early stage Perjeta...
Feb 6, 2017
ROG.VX: APHINITY’s fine line: 5-year data raises more concerns with Perjeta
Five-year data raises more concerns over Perjeta’s scope in early stage breast cancer trial APHINITY Our updated analysis following the...
Dec 15, 2015
ROG.VX: Perjeta's precarious premise, ambitious Esbriet aspirations
Initiation of Coverage of Roche: Underweight - Target Price CHF235 We see major risks over Herceptin add-on Perjeta in breast cancer...
Feb 8, 2015
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page